DNA疫苗能否预防恰加斯病?临床前研究系统综述
结果显示疫苗可降低寄生虫血症、改善部分小鼠模型生存并诱导以IFN-γ、IgG2a和CD8+ T细胞为特征的Th1免疫,减轻炎症、组织病理与心脏损伤,但保护多不完全。
要点
- DNA疫苗可诱导Th1免疫并降低寄生虫血症与组织损伤
- 保护常为部分性,罕有完全灭菌性保护
- 动物背景、抗原与给药方案异质性大,证据确定性受限
核心结论
- DNA疫苗接种抗克氏锥虫可诱导Th1免疫并减少寄生虫学与组织损伤结局,但保护常为部分性且罕有灭菌性保护。
研究设计与样本
- 两名评价者独立完成研究选择、数据提取、SYRCLE偏倚风险与GRADE证据确定性评估。
主要发现
- 总体而言,接种与寄生虫血症降低及多个小鼠模型生存改善相关。
- 免疫应答以IFN-γ、IgG2a升高和CD8+ T细胞活化为特征的Th1反应为主。
- 接种还减轻炎症性、组织病理学与心脏损伤;犬模型中寄生虫负荷与心肌炎症亦降低,但保护不完全。
关键数值与推荐
- 最常见平台为裸质粒DNA、沙门菌递送构建体与佐剂化DNA疫苗。
- 主要抗原属于转唾液酸酶家族与无鞭毛体表面蛋白。
- 动物模型以BALB/c、C57BL/6与C3H/He小鼠为主,犬研究补充转化相关性。
临床怎么用
- 提示DNA疫苗平台在恰加斯病预防中具有临床前可行性,但尚不足以支持进入人群应用的确定性结论。
- 开展后续研究需统一动物背景、抗原选择、虫株、接种途径、剂量方案与随访时长以减少异质性。
局限性
- 动物背景、抗原选择、寄生虫株、接种途径、给药方案与随访时长存在显著异质性。
- 偏倚风险常不明确且报告不完整,导致无法进行荟萃分析并限制因果推断。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chagas disease, caused by Trypanosoma cruzi, remains a major neglected tropical disease with limited treatment options. DNA-based vaccination has been explored as a preventive strategy, but its overall efficacy and translational value remain uncertain. Despite encouraging preclinical findings, the evidence on DNA-based vaccines against T. cruzi remains heterogeneous and has not been systematically integrated across outcomes. A comprehensive review is therefore needed to contextualize the current knowledge and define the translational relevance of this platform. To systematically review preclinical in vivo evidence on the efficacy of DNA-based vaccination against T. cruzi, focusing on parasitological, immunological, histopathological, and cardiac outcomes. PubMed/MEDLINE, Scopus, Embase, and Web of Science were searched without date restrictions. Eligible studies were controlled in vivo experiments evaluating DNA vaccines against T. cruzi in animal models. Two reviewers performed study selection, data extraction, risk-of-bias (SYRCLE) and certainty of evidence (GRADE) assessment independently. Thirty preclinical studies were included. Murine models predominated, especially BALB/c, C57BL/6, and C3H/He mice, although canine studies added translational relevance. Naked plasmid DNA, Salmonella-delivered constructs, and adjuvanted DNA vaccines were the most common platforms. The principal antigens belonged to the trans-sialidase family and amastigote surface proteins. Overall, vaccination was associated with reduced parasitemia, improved survival in several murine models, Th1 immune responses characterized by increased IFN-γ, IgG2a, and CD8+ T-cell activation, as well as attenuation of inflammatory, histopathological, and cardiac damage. In canine models, vaccination also reduced parasite burden and myocardial inflammation, although protection remained incomplete. Confidence in the evidence was limited by substantial heterogeneity in animal background, antigen selection, parasite strain, inoculation route, dosing regimens, and follow-up duration. Frequent unclear risk of bias and incomplete reporting prevented meta-analysis and constrain causal inference. DNA-based vaccination against T. cruzi can induce Th1 immunity and reduce parasitological and tissue injury outcomes, but protection is often partial and rarely sterilizing.
引用
- Khan IA, Dos Santos EC, Novaes RD, et al. Can a DNA vaccine protect against Chagas disease? A systematic review of preclinical studies. Vaccine. 2026. PMID: 42085749. doi:10.1016/j.vaccine.2026.128654
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。